Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.

Bacterial DNA and synthetic CpG-oligodeoxynucleotides (ODNs) derived thereof have attracted attention because they activate cells of the immune system in a sequence-dependent manner. Here we investigated the potential of CpG-ODNs to cause proliferation, cytokine production, and regulation of surface molecules in human B-chronic lymphocytic leukemia (CLL) cells. CpG-ODN induced proliferation in both B-CLL cells and normal B cells; however, only B-CLL cells increased proliferative responses when CpG-ODN was added to co-cultures of CD40-ligand transfected mouse fibroblasts (CD40LF) and B cells. Production of interleukin-6 and tumor necrosis factor alpha was detectable at borderline levels, using CpG-ODN as the only stimulus. In contrast, when CpG-ODN was added to co-cultures of B cells and CD40LF, a strong increase in cytokine production occurred in B-CLL cells as well as in normal B cells. The surface molecules CD40, CD58, CD80, CD86, CD54, and MHC class I molecules were up-regulated in B-CLL cells, whereas CD95 expression was not influenced by CpG-ODN stimulation. The same pattern of surface molecule regulation was observed in normal B cells, but up-regulation of CD40 was significantly stronger in B-CLL cells. Costimulation with CpG-ODN and CD40LF resulted in further up-regulation of CD58, CD80, CD86, and MHC class I molecules. In contrast, CD95 expression induced by CD40-ligation was inhibited by CpG-ODN. CpG-ODN activated B-CLL cells acquired a strong stimulatory capacity toward T cells in allogeneic mixed lymphocyte reaction. This effect was completely inhibited by a combination of anti-CD80 and anti-CD86 monoclonal antibody. Taken together, these findings suggest the possible use of CpG-ODN for immunotherapeutic strategies in patients with B-CLL.

[1]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.

[2]  E. Kuramoto,et al.  Synthetic Oligonucleotides with Particular Base Sequences from the cDNA Encoding Proteins of Mycobacterium bovis BCG Induce Interferons and Activate Natural Killer Cells , 1992, Microbiology and immunology.

[3]  Marc C. Jacob,et al.  Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. , 1998, Blood.

[4]  A. Krieg,et al.  Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. , 1998, Journal of immunology.

[5]  Fraser Dw.  Letter: Whooping-cough vaccination. , 1976, British medical journal.

[6]  D. Wallach,et al.  Aderka, D. et al. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor- or -. Blood 81, 2076−2084 , 1993 .

[7]  H. Mellstedt,et al.  Downregulation of the CD95 receptor and defect CD40‐mediated signal transduction in B‐chronic lymphocytic leukemia cells , 1998, European journal of haematology.

[8]  J. Karras,et al.  Unmethylated CpG motifs protect murine B lymphocytes against Fas-mediated apoptosis. , 1997, Cellular immunology.

[9]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[10]  T. Kipps,et al.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.

[11]  K. Heeg,et al.  Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor‐α‐mediated shock , 1997, European journal of immunology.

[12]  J. Gribben,et al.  Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. , 1997, Blood.

[13]  M. Hurme,et al.  Diminished production of interleukin‐6 in chronic lymphocytic leukaemia (B‐CLL) cells from patients at advanced stages of disease , 1998, British journal of haematology.

[14]  P. Lipsky,et al.  Activation of human B cells by phosphorothioate oligodeoxynucleotides. , 1996, The Journal of clinical investigation.

[15]  M. Mescher,et al.  ICAM‐1 and B7‐1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM‐1 , 1999, European journal of immunology.

[16]  R. Vabulas,et al.  Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells , 1998, European journal of immunology.

[17]  J. Gribben,et al.  Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. , 1996, Blood.

[18]  D. Klinman,et al.  Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. , 1996, Journal of immunology.

[19]  G. Weiner,et al.  Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. , 1997, Blood.

[20]  L. Trentin,et al.  B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. , 1997, Cancer research.

[21]  G. Freeman,et al.  Role of the CD40 and CD95 (APO‐1/Fas) antigens in the apoptosis of human B‐cell malignancies , 1997, British journal of haematology.

[22]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[23]  L. Rassenti,et al.  Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. , 1997, Journal of immunology.

[24]  G. Weiner,et al.  Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Banchereau,et al.  Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. , 1992, Blood.

[26]  T. Kipps,et al.  Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.

[27]  G. Gaidano,et al.  Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. , 1995, Clinical immunology and immunopathology.

[28]  S. O'brien,et al.  Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. , 1995, Blood.

[29]  M. Turner,et al.  TUMOUR NECROSIS FACTOR AS AN AUTOCRINE TUMOUR GROWTH FACTOR FOR CHRONIC B-CELL MALIGNANCIES , 1988, The Lancet.

[30]  K. Heeg,et al.  Bacterial DNA causes septic shock , 1997, Nature.

[31]  M. Yellin,et al.  T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. , 1994, Journal of immunology.

[32]  R. Foà,et al.  Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. , 1990, Blood.

[33]  P. Lipsky,et al.  The role of CD40-CD40 ligand interaction in human T cell-B cell collaboration. , 1994, Journal of immunology.

[34]  H. Mischak,et al.  CpG‐DNA‐specific activation of antigen‐presenting cells requires stress kinase activity and is preceded by non‐specific endocytosis and endosomal maturation , 1998, The EMBO journal.

[35]  R. V. van Lier,et al.  Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. , 1995, Blood.

[36]  J. Plumas,et al.  Malignant B lymphocytes from non‐Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: An important role of co‐stimulatory molecules CD80 (B7‐1) and CD86 (B7‐2) in stimulation by tumor cells , 1995, European journal of immunology.

[37]  O. Majdic,et al.  Role of accessory cells in cytokine production by T cells in chronic B-cell lymphocytic leukemia. , 1995, Blood.

[38]  Adrian Bird,et al.  The essentials of DNA methylation , 1992, Cell.

[39]  D. Wallach,et al.  Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. , 1993, Blood.

[40]  J. Ceuppens,et al.  CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules , 1997, Leukemia.

[41]  K. Heeg,et al.  DNA activates human immune cells through a CpG sequence‐dependent manner , 1999, Immunology.

[42]  A. Krieg,et al.  CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. , 1998, Journal of immunology.

[43]  M. Schuler,et al.  Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. , 1998, Cellular immunology.